T Cell Non-Hodgkin Lymphoma

P2, N=120, Not yet recruiting, BeBetter Med Inc

Collectively, these findings have significant implications for the rationale design of combinatorial strategies targeting immune checkpoints, including PD-1. We have identified transcriptional programs, driven by oncogenic transcription factors, and constituents of the TME as therapeutic vulnerabilities in CTCL, and hope that the CTCL atlas constructed will provide a valuable resource for future studies exploiting these therapeutic vulnerabilities.

The patient achieved complete remission (CR) after 6 cycles of chidamide plus CHOP chemotherapy, with no evidence of recurrence at 6 months. This case broadens the recognized cutaneous spectrum of AITL and underscores the importance of considering lymphoma in the differential diagnosis of unexplained subcutaneous nodules.

We further demonstrate that a privacy-preserving, mechanistic digital twin can serve as a clinically actionable tool for early risk stratification and personalized intervention, while providing a scalable blueprint for collaborative systems immunology research. Definitive validation of clinical utility requires a randomised controlled trial in which treatment decisions are prospectively guided by the digital twin's predictions.

Our results suggest that EZH2 may play a functional role in the maintenance and progression of at least a subset of canine T-cell lymphoma and may represent a potential driver of tumor malignancy. These findings contribute to a deeper understanding of lymphomagenesis and support the potential of EZH2 as a therapeutic target in canine T-cell lymphoma.

We have uncovered the dynamic changes in PBMCs of newly diagnosed NK/T cell lymphoma patients and identified specific characteristics in patients with high intracellular EBV levels. Our findings provide new insights into the immunopathogenesis of NKTCL, offering valuable information for immune-based stratification and the development of therapeutic strategies.

This study identifies IRENA as an independent prognostic biomarker for nodal PTCL patients, revealing its role in the self-organizing activation of RHOA GTPase. Targeting the IRENA/RHOA/MAPK signaling axis by ASO may represent a potential therapeutic strategy for PTCL.

Despite advances such as brentuximab vedotin-based regimens in CD30-positive disease, relapse rates remain high, particularly in relapsed/refractory (R/R) PTCL...Novel targeted agents, epigenetic therapies, bispecific antibodies, and emerging cellular approaches are reshaping the therapeutic landscape and may serve as effective bridges to allo-HCT or as post-transplant maintenance strategies. This review summarizes current evidence regarding the role of allo-HCT in PTCL, discusses patient selection and transplant-related variables, and explores evolving strategies aimed at improving survival while minimizing toxicity.

For TZL, extended follow-up studies are needed due to its indolent behavior. Although sPD-L1 and mRNA levels did not correlate with outcome, their diagnostic and prognostic utility merits further investigation and methodologic refinement.

Cumulatively, these therapies illustrate both the progress and the ongoing challenges of biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic sequencing, and variability in evidence maturity across targeted strategies. While pirtobrutinib and brentuximab vedotin are supported by increasingly robust clinical evidence in selected lymphoma subtypes, the role of belinostat remains constrained by modest response rates and limited randomized data, underscoring the continued need for biomarker refinement and more precisely individualized therapeutic approaches in NHL precision medicine.

This report explores the clinical and histological manifestations of GMF, features distinguishing GMF from other granulomatous diseases, such as IGD, and the prognostic significance of distinguishing GMF from classic mycosis fungoides. We aimed to raise awareness among physicians regarding this rare disease and emphasize the characteristic histological features of GMF that can be confused with other types of mycosis fungoides.

Antibody screen acted as a whistleblower for an undiagnosed aggressive lymphoma. Thus, it will be prudent to look beyond the obvious in complex cases, and a detailed workup will help put together all parts of the jigsaw puzzle.